Titan Pharmaceuticals, Inc. (TTNP) Reaches $0.60 52-Week Low; Profile of 17 Analysts Covering Wells Fargo & Company (WFC)

May 5, 2018 - By Hazel Jackson

Wells Fargo & Company (NYSE:WFC) Logo

The stock of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) hit a new 52-week low and has $0.57 target or 5.00% below today’s $0.60 share price. The 7 months bearish chart indicates high risk for the $12.72 million company. The 1-year low was reported on May, 5 by Barchart.com. If the $0.57 price target is reached, the company will be worth $636,100 less. The stock decreased 26.83% or $0.22 during the last trading session, reaching $0.6. About 522,042 shares traded or 375.97% up from the average. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has declined 67.50% since May 5, 2017 and is downtrending. It has underperformed by 79.05% the S&P500.

Among 39 analysts covering Wells Fargo & Company (NYSE:WFC), 17 have Buy rating, 8 Sell and 14 Hold. Therefore 44% are positive. Wells Fargo & Company had 149 analyst reports since July 29, 2015 according to SRatingsIntel. On Monday, April 30 the stock rating was upgraded by Macquarie Research to “Outperform”. The firm has “Neutral” rating given on Wednesday, April 6 by Guggenheim. As per Monday, February 5, the company rating was downgraded by J.P. Morgan. The firm has “Sell” rating by BMO Capital Markets given on Friday, July 14. The stock of Wells Fargo & Company (NYSE:WFC) has “Overweight” rating given on Monday, April 16 by Barclays Capital. The company was maintained on Thursday, September 28 by Nomura. On Wednesday, April 12 the stock rating was downgraded by Rafferty to “Sell”. The stock of Wells Fargo & Company (NYSE:WFC) has “Outperform” rating given on Wednesday, April 12 by Evercore. The rating was downgraded by Berenberg on Friday, July 21 to “Sell”. The stock of Wells Fargo & Company (NYSE:WFC) has “Buy” rating given on Monday, February 5 by Nomura. See Wells Fargo & Company (NYSE:WFC) latest ratings:

30/04/2018 Broker: Keefe Bruyette & Woods Rating: Buy Upgrade
30/04/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $60 New Target: $57 Maintain
30/04/2018 Broker: Macquarie Research Old Rating: Neutral New Rating: Outperform Upgrade
23/04/2018 Broker: Susquehanna Rating: Hold New Target: $58.0000 Maintain
16/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $71 New Target: $66 Maintain
16/04/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $64 New Target: $60 Maintain
16/04/2018 Broker: Buckingham Research Old Rating: Buy New Rating: Buy Old Target: $75 New Target: $70 Maintain
15/04/2018 Broker: Jefferies Rating: Hold New Target: $56.0000 Maintain
15/04/2018 Broker: Piper Jaffray Rating: Hold New Target: $58.0000 Maintain
15/04/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $55.0000 Maintain

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company has market cap of $12.72 million. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. It currently has negative earnings. The firm offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

Analysts await Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report earnings on May, 9. They expect $-0.13 EPS, up 18.75% or $0.03 from last year’s $-0.16 per share. After $-0.17 actual EPS reported by Titan Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -23.53% EPS growth.

More news for Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” on May 04, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings” and published on May 02, 2018 is yet another important article.

Wells Fargo & Company, a diversified financial services company, provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. The company has market cap of $255.44 billion. The Company’s Community Banking segment offers checking, savings, market rate, and individual retirement accounts, as well as time deposits and remittances; and lines of credit, automobile floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards. It has a 12.51 P/E ratio. This segment also provides equipment leases, real estate and other commercial financing, small business administration financing, venture capital financing, cash management, payroll services, retirement plans, merchant payment processing, and private label financing solutions, as well as purchases retail installment contracts.

Investors sentiment increased to 0.75 in Q4 2017. Its up 0.02, from 0.73 in 2017Q3. It improved, as 63 investors sold Wells Fargo & Company shares while 746 reduced holdings. 138 funds opened positions while 466 raised stakes. 3.64 billion shares or 0.11% less from 3.65 billion shares in 2017Q3 were reported. Synovus Fincl Corp owns 154,721 shares. Wesbanco Bankshares Inc owns 167,779 shares or 0.69% of their US portfolio. Aqr Capital Mngmt owns 5.58 million shares. Moreover, Boulegeris Inc has 0.5% invested in Wells Fargo & Company (NYSE:WFC) for 15,971 shares. Ironwood has 3,144 shares. Rothschild Asset Incorporated accumulated 613,999 shares. Invesco stated it has 0.44% of its portfolio in Wells Fargo & Company (NYSE:WFC). Grandfield Dodd Limited Liability Com has invested 0.12% of its portfolio in Wells Fargo & Company (NYSE:WFC). Ami Inv stated it has 5.44% of its portfolio in Wells Fargo & Company (NYSE:WFC). Loews has 4,501 shares for 0% of their portfolio. Arcadia Invest Management Mi has invested 0.15% in Wells Fargo & Company (NYSE:WFC). Winfield Associates reported 0.15% in Wells Fargo & Company (NYSE:WFC). Moreover, Btim has 0.02% invested in Wells Fargo & Company (NYSE:WFC) for 28,067 shares. Patten Gru stated it has 1,100 shares or 0.03% of all its holdings. Kessler Invest Group Limited Liability reported 29 shares or 0% of all its holdings.

More notable recent Wells Fargo & Company (NYSE:WFC) news were published by: 247Wallst.com which released: “Wells Fargo’s Tim Sloan Remains One of America’s Worst CEOs” on May 05, 2018, also Seekingalpha.com with their article: “Wells Fargo: Where Is The Upside?” published on May 03, 2018, Seekingalpha.com published: “Wells Fargo: Buying Opportunity?” on April 25, 2018. More interesting news about Wells Fargo & Company (NYSE:WFC) were released by: 247Wallst.com and their article: “Wells Fargo Settles Federal Claims for $1 Billion” published on April 20, 2018 as well as Seekingalpha.com‘s news article titled: “Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting” with publication date: May 05, 2018.

The stock increased 1.69% or $0.87 during the last trading session, reaching $52.41. About 16.66 million shares traded. Wells Fargo & Company (NYSE:WFC) has declined 7.75% since May 5, 2017 and is downtrending. It has underperformed by 19.30% the S&P500.

Since November 17, 2017, it had 0 insider buys, and 1 insider sale for $292,234 activity. $292,234 worth of Wells Fargo & Company (NYSE:WFC) was sold by Codel Franklin R.

Wells Fargo & Company (NYSE:WFC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: